This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.

Sandbox Reserved 1687

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Revision as of 05:03, 12 October 2021

Ebola Virus RNA-Dependent RNA Polymerase

1 Disease
2 RNA Classification
3 Function of RNA-Dependent RNA Polymerase
4 Structural Features of Ebola Virus RNA-Dependent RNA Polymerase
5 RNA Transcription and Translation

Disease

Ebola virus (EBOV) causes Ebola virus disease (EVD), a fatal hemorrhagic disease discovered in 1976.^[1] Sources of infection are mainly linked with “hunting wildlife, exposure to animal carcasses found in the forest, or contact with the putative virus reservoir, bats”.^[2]

EVD pathogenesis in humans consists of three phases with symptoms normally occurring after an incubation period of 2-21 days.^[3] In the first phase, symptoms during the first few days include nonspecific fever, headache, and myalgia.^[4] This is followed by a “gastrointestinal phase” characterized by symptoms including diarrhea, vomiting, abdominal discomfort, and dehydration.^[5] The final and advanced phase of the illness consist of kidney and liver function failure, often resulting in “metabolic compromise, convulsion, shock, and death due to mucosal bleeding, bloody diarrhea, and multi-organ failure within 16 days after the first symptoms appear”.^[6]

Since EBOV's discovery, there have been 20 known outbreaks restricted primarily to African countries with minor spread to neighboring countries.^[7] The most recent outbreak of Ebola occurred during a three-month span in the Democratic Republic of the Congo this year, the country’s 4th in the past three years.[1] Since its start in February, there was a total of eleven confirmed cases with six recoveries and six deaths and one probable case emanating from four health zones in North Kivu.[2] There is also an ongoing outbreak in Guinea, West Africa which started in the same month as the outbreak in the DRC.[3]

There is currently no vaccine for EVD, but there are currently eight vaccine candidates in human clinical trials that all target the Ebola virus glycoprotein (GP), one of the nine known proteins to be expressed by the virus’s genome.^[8] However, these vaccines are different from each other in the immune responses they elicit, the antigen delivery system, and their respective side-effect profiles.^[9]

RNA Classification

Ebola is part of the Filoviridae family of single-stranded negative-sense RNA viruses of approximately 19 kb.^[10] The 19 kb RNA encodes for “glycoproteins (i.e., GP, sGP, ssGP), nucleoproteins, virion proteins (i.e., VP 24, 30, 40) and the RNA dependent RNA polymerase”.^[11] In EBOV, the RNA dependent RNA polymerase in conjunction with NP, VP30, and VP35 form the RNP complex in viral genome transcription and replication.^[12] RDRP binds to the 3’ leader promoter and changes EBOV’s negative-sense RNA into positive-sense messenger RNA to produce Ebola proteins that produce new viral particles (virions).^[13]

Function of RNA-Dependent RNA Polymerase

RNA dependent RNA polymerases (RdRp) are critical to the replication of RNA viruses.^[14]

Structural Features of Ebola Virus RNA-Dependent RNA Polymerase

RNA Transcription and Translation

References

↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Malvy D, McElroy AK, de Clerck H, Gunther S, van Griensven J. Ebola virus disease. Lancet. 2019 Mar 2;393(10174):936-948. doi: 10.1016/S0140-6736(18)33132-5. Epub, 2019 Feb 15. PMID:30777297 doi:http://dx.doi.org/10.1016/S0140-6736(18)33132-5
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Furuyama W, Marzi A. Ebola Virus: Pathogenesis and Countermeasure Development. Annu Rev Virol. 2019 Sep 29;6(1):435-458. doi:, 10.1146/annurev-virology-092818-015708. PMID:31567063 doi:http://dx.doi.org/10.1146/annurev-virology-092818-015708
↑ Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Ansari AA, Gershwin ME, Anaya JM. Ebola virus disease: An emerging and re-emerging viral threat. J Autoimmun. 2020 Jan;106:102375. doi: 10.1016/j.jaut.2019.102375. Epub 2019 Dec , 3. PMID:31806422 doi:http://dx.doi.org/10.1016/j.jaut.2019.102375
↑ Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Ansari AA, Gershwin ME, Anaya JM. Ebola virus disease: An emerging and re-emerging viral threat. J Autoimmun. 2020 Jan;106:102375. doi: 10.1016/j.jaut.2019.102375. Epub 2019 Dec , 3. PMID:31806422 doi:http://dx.doi.org/10.1016/j.jaut.2019.102375
↑ Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Ansari AA, Gershwin ME, Anaya JM. Ebola virus disease: An emerging and re-emerging viral threat. J Autoimmun. 2020 Jan;106:102375. doi: 10.1016/j.jaut.2019.102375. Epub 2019 Dec , 3. PMID:31806422 doi:http://dx.doi.org/10.1016/j.jaut.2019.102375
↑ Tchesnokov EP, Raeisimakiani P, Ngure M, Marchant D, Gotte M. Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus. Sci Rep. 2018 Mar 5;8(1):3970. doi: 10.1038/s41598-018-22328-3. PMID:29507309 doi:http://dx.doi.org/10.1038/s41598-018-22328-3

Retrieved from "http://52.214.119.220/wiki/index.php/Sandbox_Reserved_1687"

@@ Line 15: / Line 15: @@
 ==Function of RNA-Dependent RNA Polymerase==
+RNA dependent RNA polymerases (RdRp) are critical to the replication of RNA viruses.<ref>DOI:10.1038/s41598-018-22328-3</ref>
 ==Structural Features of Ebola Virus RNA-Dependent RNA Polymerase==
+==RNA Transcription and Translation==
 </StructureSection>
 == References ==
 <references/>

Sandbox Reserved 1687

From Proteopedia

Revision as of 05:03, 12 October 2021

Ebola Virus RNA-Dependent RNA Polymerase

Contents

Disease

RNA Classification

Function of RNA-Dependent RNA Polymerase

Structural Features of Ebola Virus RNA-Dependent RNA Polymerase

RNA Transcription and Translation

References

Views

Personal tools

Navigation

Search

Toolbox